Konrad Muller-Hermelink
Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network
Klapper W, Möller P, Barth T, Muller-Hermelink K, Rosenwald A, Ott G, Pileri S, Ralfkiaer E, Rymkiewicz G, van Krieken J, Wacker H, Unterhalt M, Hiddemann W, Dreyling M, Stein H, Loddenkemper C, Hoster E, Determann O, Oschlies I, van der Laak J, Berger F, Bernd H, Cabeçadas J, Campo E, Cogliatti S, Hansmann M, Kluin P, Kodet R, Krivolapov Y, for the European MCL Network. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. Journal of hematopathology 2009
16.06.2009Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network
16.06.2009Journal of hematopathology 2009
Klapper Wolfram, Möller Peter, Barth Thomas, Muller-Hermelink Konrad, Rosenwald Andreas, Ott German, Pileri Stefano, Ralfkiaer Elisabeth, Rymkiewicz Grzegorz, van Krieken Johan, Wacker Hans, Unterhalt Michael, Hiddemann Wolfgang, Dreyling Martin, Stein Harald, Loddenkemper Christoph, Hoster Eva, Determann Olaf, Oschlies Ilske, van der Laak Jeroen, Berger Françoise, Bernd Heinz, Cabeçadas José, Campo Elias, Cogliatti Sergio B., Hansmann Martin, Kluin Philip, Kodet Roman, Krivolapov Yuri, for the European MCL Network
Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Rehwald U, Engert A, Diehl V, Muller-Hermelink K, Rüdiger T, Driessen C, Morschhauser F, Staak J, Sieber M, Reiser M, Schulz H, German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-4.
15.01.2003Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
15.01.2003Blood 2003; 101:420-4
Rehwald Ute, Engert Andreas, Diehl Volker, Muller-Hermelink Konrad, Rüdiger Thomas, Driessen Christoph, Morschhauser Franck, Staak Jan Oliver, Sieber Markus, Reiser Marcel, Schulz Holger, German Hodgkin Lymphoma Study Group (GHSG)